Skip to content
AdminApr 12, 2018< 1 min read

Real-world evidence platform developer Aetion nabs Amgen-backed $36M Series B

The passage of the 21st Century Cures Act spurred growing interest in the use of real-world data for drug development and regulatory processes. Venture capitalists have noticed that trend and are putting big money behind a company that develops software just for that practice. Aetion, whose analytics platform helps biopharma companies and payers better understand how drugs work in the real world, just secured $36.4 million in series B funding. The round was led by New Enterprise Associates and counted Amgen Ventures among its investors.

Read More